A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively in advanced epithelial ovarian cancer - IPLA-OVCA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507732-20-00

Enrollment

220

Registered

2023-08-30

Start date

2019-11-29

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced epithelial ovarian cancer stage III-IV

Brief summary

Time (days) to start of adjuvant chemotherapy after cytoreductive surgery

Detailed description

Postoperative complications, postoperative morbidity, quality of recovery, cardiac and renal impairment and overall survival

Interventions

DRUGSODIUM CHLORIDE

DRUGROPIVACAINE HYDROCHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time (days) to start of adjuvant chemotherapy after cytoreductive surgery	—

Secondary

Measure	Time frame
Postoperative complications, postoperative morbidity, quality of recovery, cardiac and renal impairment and overall survival	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026